Journal
LEUKEMIA & LYMPHOMA
Volume -, Issue -, Pages -Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2023.2232494
Keywords
Acute myeloid leukemia (AML); programmed cell death ligand-1 (PD-L1); JAK2 / STAT mutation; combined positive score (CPS)
Categories
Ask authors/readers for more resources
Although PD-L1 overexpression is observed in solid tumors, its expression patterns in acute myeloid leukemia (AML) are not well studied. This study shows that PD-L1 expression is significantly upregulated in AML cases with activating mutations in JAK2/STATs compared to wildtype controls. There is a positive correlation between phosphorylated STAT3 expression and PD-L1 expression. The CPS scoring system could be used to quantitatively measure PD-L1 expression in leukemias and JAK2/STATs mutant AML could be potential candidates for checkpoint inhibitor trials.
Even though overexpression of the immune checkpoint protein, programmed cell death ligand-1 (PD-L1), is observed in solid tumors, its expression patterns in acute myeloid leukemia remain understudied. As activation of the JAK/STAT pathway has been shown to enhance PD-L1 expression in preclinical models, we evaluated biopsies from AML patients with activating mutations in JAK2/STATs. PD-L1 expression was significantly upregulated in JAK2/STAT mutant cases when compared to JAK2 wildtype controls as demonstrated by PD-L1 immunohistochemistry staining and quantified using the combined positive score (CPS) system. There is significant overexpression of phosphorylated STAT3 expression in patients with oncogenic JAK2 activation and a positive correlation between p-STAT3 and PD-L1 expression. In conclusion, we demonstrate the CPS scoring system could be applied as a quantitative measure of PD-L1 expression in leukemias and that JAK2/STATs mutant AML can be potential candidates for checkpoint inhibitor trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available